Sunitinib malate (SUTENT©; Pfizer, Inc., New York, NY) is an oral VEGF TKI approved as first-line treatment for advanced RCC 5, which has demonstrated superior clinical and quality of life (QOL) outcomes compared to IFN-α6,7. The gene discussed is VEGFA; the disease is renal cell carcinoma.